Vimarsana
Biggest News Aggregation in the World

Page 46 - Program Update News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Program Update. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Program Update Today - Breaking & Trending Today

CORRECTION FROM SOURCE: F3 Hits 4.0m of 29.3% U3O8 Within 10.3% Over 12.0m -November 13, 2023 at 11:35 am EST - Vimarsana News

CORRECTION FROM SOURCE: F3 Hits 4.0m of 29.3% U3O8 Within 10.3% Over 12.0m -November 13, 2023 at 11:35 am EST

F3 Uranium Corp is pleased to announce initial assay results for the ongoing drill program, including PLN23-079 which returned 12.0m of 10.3% U3O8, including a hig...

CORRECTION FROM SOURCE: F3 Hits 4.0m of 29.3% U3O8 Within 10.3% Over 12.0m - Vimarsana News

CORRECTION FROM SOURCE: F3 Hits 4.0m of 29.3% U3O8 Within 10.3% Over 12.0m

The following amendments have been made to the announcement headed "F3 Hits 4.0m of 29.3% U3O8 Within 10.3% Over 12.0m" released on 13, 2023: In the paragraph headed "Assay Highlight" the following correction has been made: The third bullet has been... - Veroeffentlicht am 13.11.2023

Barton County Commission meeting agenda (11/7) - Vimarsana News

Barton County Commission meeting agenda (11/7)

The Commission meeting will be live-streamed through Microsoft Teams.

Northisle Copper and Gold Commences Phase 3 Drill Program at Northwest Expo - Vimarsana News

Northisle Copper and Gold Commences Phase 3 Drill Program at Northwest Expo

Real-Time News, Market Data and Stock Quotes For Junior Mining Stocks.

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis - Nkarta (NASDAQ:NKTX) - Vimarsana News

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis - Nkarta (NASDAQ:NKTX)

New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B